knowledge -WSS

knowledge

author：entertainment 2025-09-28 18:40:01 - browse：75245

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Can U.S. cancer drug shortages be fixed?

hotspot

explore

hotspot

WSS

Pig kidney works a record two months in donated body

FDA approves updated Covid vaccines

Study: Spinal cord stimulation helps patients with paralysis walk again

How medical schools plan to diversify without affirmative action

Listen: Vivek Ramaswamy's star turn & leaky drug data

How the first Native Hawaiian psychiatrist helped diversify medicine

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

In Memoriam: Notable people who died in 2023

FDA approves updated Covid vaccines

Continuity nursing helped my family in our darkest PICU moments

Intellia plays down concerns on accidental germline transmission

Cancer drug shortages should be causing more outrage

Acelyrin, a rare IPO success, stumbles in its first big test

Novavax promises a turnaround & Lilly roils the obesity market

Roche's accidental data boosts hopes for anti

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Will the IRA bring competition to the biologics market?

leisure time

FDA approves updated Covid vaccines

Kellogg’s is going to war over Mexico’s nutrition label rules

PBMs are inflating the cost of generic drugs. They must be reined in

DeSantis wants to import drugs. Biden’s FDA blasted his plan

How the first Native Hawaiian psychiatrist helped diversify medicine

Can U.S. cancer drug shortages be fixed?

hotspot

explore

hotspot

explore